The POZ 100 (2010)
To ensure that high-level promises are kept and to get the funding we need to effectively implement the tenets of the National HIV/AIDS Strategy, we need our A-list soldiers on the line. In that spirit, we offer the following list of 100 people we feel have great impact on HIV/AIDS in the United States today. We have many of them to thank for the progress we’ve recently made. These people are also likely to keep the heat on in the months and years to come.
December 31, 2010 — POZ
HIV prevention gathers steam
For the first time, a microbicide gel — a product that could be used by women — had been shown to reduce the risk of acquiring HIV.
December 23, 2010 — MedPage Today
No Turning Back: Pursuing the promise of HIV prevention
Last week, 2,499 gay and bisexual men and transgender women from four continents made history when the iPrEx HIV prevention trial reported positive results.
December 10, 2010 — Huffington Post
Daily pill greatly lowers AIDS risk, study finds
Inthe study, published Tuesday by theNew England Journal of Medicine, researchers found that the men taking Truvada, a common combination of two antiretroviral drugs, were 44 percent less likely to get infected with the virus that causes AIDS than an equal number taking a placebo.
November 23, 2010 — New York Times
New Lines of Attack in H.I.V. Prevention
In the next few months, said Mitchell Warren, executive director of AVAC, an advocacy group for AIDS prevention, “we’re going to see a cascade of results” from trials of what is called “oral pre-exposure prophylaxis,” or “oral prep” for short. In them, men and women who are not infected with the AIDS virus but who regularly engage in high-risk sex, like anal sex without condoms or sex for money with strangers, take a daily dose of one or two of the antiretroviral drugs normally taken by infected people.
November 8, 2010 — New York Times
SA leads way in anti-HIV tests
Mitchell Warren, executive director of global advocacy organisation AVAC, said: “Not only is South Africa at the forefront of testing individual approaches but it is leading the development of combination prevention, which is clearly the only way to truly end the epidemic.”
May 26, 2010 — Times (South Africa)
Ending AIDS: Grounds for despair, cynicism or hope?
This year, for the first time, we mark the Day with hope based on evidence from a trial in humans that shows that an AIDS vaccine is possible.
May 17, 2010 — Huffington Post
State of the ART of microbicides
The microbicides field has undoubtedly moved and shifted a lot in the past decade. Now, with first generation microbicides candidate products up and gone, antiretroviral treatment (ART)-drug based microbicides in spotlight, and only three major microbicides efficacy studies remaining, the need to lobby for increased funding of microbicides research and development, was never so compelling.
May 14, 2010 — Citizen News Service
AIDS `Next Big Thing’ Rests on Study of Gilead Disease Prevention Cocktail
Gilead Sciences Inc. may learn this year whether its drugs for treating HIV can also stop people from catching the virus in the first place. The approach may help curb the AIDS pandemic in poor countries and bring Gilead $1 billion a year in additional U.S. sales, said Josh Schimmer, an analyst at Leerink Swann & Co. in Boston. Most investors aren’t alert to the potential benefit, he said. Researchers are compiling the first data from 10 trials involving more than 20,000 people, and initial results may be available in July.
April 1, 2010 — Bloomberg
→ Continue through the archives. Find articles from 2009 and older.